Zoledronic acid attenuates ischemic brain injury by promoting ETS2 and MSR1 expression
International Immunology · 2025
DOI: 10.1093/intimm/dxaf010 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunology, 2025. Verfasst von Kento Otani und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroinflammation and Repair, Medical Research Laboratory, Institute for Integrated Research, Institute of Science Tokyo, Tokyo 113-851…. Hauptthemen laut MEDLINE: Brain Ischemia, Zoledronic Acid, Proto-Oncogene Protein c-ets-2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: CREST from AMED, Grant-in-Aid for Scientific Research on Innovative Areas (Dynamic Regulation of Brain Function by the Glia decoding, JSPS KAKENHI Grants-in-Aid for Scientific Research.
Abstract (Originalsprache)
Intracerebral inflammation and brain swelling often worsen the functional prognosis of stroke patients. Post-stroke inflammation is resolved by the removal of inflammatogenic damage-associated molecular patterns (DAMPs) through macrophage scavenger receptor 1 (MSR1); however, therapeutics promoting MSR1 expression efficiently have not been developed. We identified ETS2 as a transcription factor that promoted MSR1 expression in myeloid cells by epigenetic molecular screening. Increased Ets2 expression in macrophages enhanced MSR1 expression and the internalization of peroxiredoxins (PRXs), pivotal inflammatogenic DAMPs in ischemic stroke. By evaluation of chemicals inducing Ets2 expression, we discovered that zoledronic acid increased Ets2 and Msr1 expression in macrophages. Post-stroke administration of zoledronic acid significantly suppressed cerebral inflammation by increasing MSR1 expression in infiltrating myeloid cells, attenuating ischemic neuronal injury in a myeloid Ets2-dependent manner. Thus, epigenetic molecular screening that enhances MSR1 expression is a useful approach to developing therapeutics that improve functional prognosis after ischemic stroke.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuroinflammation and Repair, Medical Research Laboratory, Institute for Integrated Research, Institute of Science Tokyo, Tokyo 113-8510, Japan.
- Core Research for Evolutionary Medical Science and Technology (CREST), Japan Agency for Medical Research and Development (AMED), Tokyo 100-0004, Japan.
- Stroke Renaissance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan.
- Division of Biochemistry, Faculty of Pharmacy and Graduate School of Pharmaceutical Science, Keio University, Tokyo 105-8512, Japan.
- Institute of Fermentation Sciences (IFeS), Faculty of Food and Agricultural Sciences, Fukushima University, Fukushima 960-1296, Japan.
- International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo (IMSUT), Tokyo 108-8639, Japan.
ORCID-Profile: Seiichiro Sakai, Koji Hase
Förderung
- CREST from AMED
- Grant-in-Aid for Scientific Research on Innovative Areas (Dynamic Regulation of Brain Function by the Glia decoding
- JSPS KAKENHI Grants-in-Aid for Scientific Research
Zitieren
APA
Otani, K., Koyama, R., Tsuyama, J., Sakai, S., Hase, K., & Shichita, T. (2025). Zoledronic acid attenuates ischemic brain injury by promoting ETS2 and MSR1 expression. International Immunology. https://doi.org/10.1093/intimm/dxaf010
Vancouver
Otani K, Koyama R, Tsuyama J, Sakai S, Hase K, Shichita T. Zoledronic acid attenuates ischemic brain injury by promoting ETS2 and MSR1 expression. International Immunology. 2025. doi:10.1093/intimm/dxaf010
BibTeX
@article{Otani2025,
author = {Otani, Kento and Koyama, Ryuki and Tsuyama, Jun and Sakai, Seiichiro and Hase, Koji and Shichita, Takashi},
title = {Zoledronic acid attenuates ischemic brain injury by promoting ETS2 and MSR1 expression},
journal = {International Immunology},
year = {2025},
doi = {10.1093/intimm/dxaf010}
}
EUVIMED